Recent Publications

Prusty,B.K., Karlas,A, Meyer,T.F., and Rudel,T. (2011).

Genome-wide RNAi screen for viral replication in mammalian cell culture

Methods Mol. Biol. 271, 383-395Direct link
3) Plotnikov A., Chuderland, D., Karamancha, Y., Livnah O., Seger, R.

Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation

Mol. Cell Biol., (2011) 31, 3515-30Direct link

Homepage

You are here: Homepage

Welcome to the official website of the ANTIFLU project – a pan-European research collaboration funded by the European Union.

ANTIFLU aims at developing innovative drugs against influenza virus infections based on a novel concept that builds on the development of drugs targeting host cell factors to preclude the development of viral resistance and ensure efficacy against upcoming pandemic influenza strains.

With a total budget of 7.8 M€ and a funding support of 6 M€ for 5 years from the European Union's Seventh Framework Programme (FP7) for Research and Technology Development, ANTIFLU is coordinated by Professor Thomas Meyer from the Max Planck Institute for Infection Biology and includes several SMEs, internationally renowned research groups and clinical institutions with extensive experience in anti-influenza treatment and clinical trials.

For further information about the ANTIFLU research, see also sections “About ANTIFLU ” and “Research areas.

Influenza A Virus Infection

The scanning electron mircrograph shows a pandemic virus strain  (A/Hamburg/04/09) of swine flu (H1N1) that destroys a human lung epthelial cell 18 hours after infection.
(Volker Brinkmann, Max Planck Institute for Infection Biology)


Next page: About ANTIFLU




Top of page